Sionna Therapeutics, Inc.

Company: Sionna Therapeutics, Inc.
Ticker: SION

Submit Your Information

If you suffered a loss on your Sionna Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Last Name*

Email*

Phone*

City

State

Country

Total # of shares

First Purchase Date

Last Purchase Date

Estimated Loss Range

Check here if you still hold any shares.

Check here if you are a current or former employee of the company.

Check here if you purchased any shares before

Additional Comments

Background

On August 10, 2026, Sionna reported topline data from its PreciSION CF Phase 2a trial and provided a corporate update. Among other items, Sionna announced a primary endpoint miss and that the Company will not advance SION-719 as an add-on to standard of care.

On this news, Sionna's stock fell $46.54, or 91.2% per share, to close at $4.10 per share on August 10, 2026

Submit Your Information